|
KMID : 0982820070060010008
|
|
Journal of Lung Cancer
2007 Volume.6 No. 1 p.8 ~ p.14
|
|
|
Four Cycles of Docetaxel and Cisplatin Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
|
|
Kim Kwang-Min
Kim Hoon-Gu
Kang Myoung-Hee
Ju Ji-Hyun
Yoou Seung-Suk
Lee Sang-Min
Kang Jung-Hun
Lee Won-Seop
|
|
|
Abstract
|
|
|
Purpose: We performed a pilot study on defining duration of docetaxel and cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer to evaluate its efficacy.
Patients and Methods: Sixteen chemo- naive patients with biopsy proven, unresectable (stage IIIB or IV) non-small cell lung cancer (NSCLC) were enrolled between January 2003 and December 2004. Treatment consisted of docetaxel (75 mg/m2/day) and cisplatin (70 mg/m2/day) every 3 week up to 4 cycles. The outcome was compared with that of a historical control group of 42 patients treated from January 1998 until December 2001, who were treated with mitomycin-C, vinorelbine, cisplatin for unresectable stage IIIB or IV NSCLC.
Results: Median age was 68 (age range 43∼72). Among 16 patients, 5 patients were stage IIIB and 11 were stage IV. Fourteen patients had performance status of 0-1 and, 2 had performace status 2 respectively. Two patients were lost due to refusal of receiving chemotherapy. By intention-to- treat-analysis, overall response rate was 44% (C.I.: 0.19∼0.68). No complete response was noted. Median time to progression (TTP) was 144 days. Overall survival (OS) was 285 days. There is no difference in TTP & OS between docetaxel, cispatin (DP) group and mitomycin, vinorelbine, cisplatin (MVP) group statistically. Neutropenia was the most common grade III or IV toxicity; (two patients had Grade III toxicity and five Grade IV toxicity). Five patients developed febrile neutropenia, and three of neutropenia patients died due to pneumonia or septic shock. The most common non-hematologic toxicity was infection. Two of 3 patients with infection required admission.
Conclusion: These findings suggested that four cycles of docetaxel and cisplatin might be as effective as MVP continous therapy for advanced NSCLC.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Docetaxel, Cisplatin, 4 cycles
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|